Crescent Grove Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Crescent Grove Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-60,000	Closed	-$21.6K	–	310
2023 Q1	$21.6K	Buy	60,000 +38,000	+173%	+$34.1K	﹤0.01%	279
2022 Q4	$19.5K	Buy	22,000 +1,000	+5%	+$1.33K	﹤0.01%	273
2022 Q3	$33K	Buy	21,000 +1,000	+5%	+$2.27K	﹤0.01%	257
2022 Q2	$40K	Hold	20,000	–	–	﹤0.01%	257
2022 Q1	$47K	Sell	20,000 -23,000	-53%	-$71.7K	﹤0.01%	291
2021 Q4	$200K	Buy	43,000 +21,000	+95%	+$130K	0.02%	284
2021 Q3	$168K	Buy	22,000 +2,000	+10%	+$17K	0.02%	257
2021 Q2	$194K	Buy	+20,000	New	+$159K	0.02%	255

Other funds holding SRNE

SlateStone Wealth Jupiter, Florida $1.31B AUM 26.51% 1-Year Est. Return

KLCM Advisors Milwaukee, Wisconsin $1.27B AUM 31.14% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return

OAJ

Ogorek Anthony Joseph Williamsville, New York $403M AUM 22.57% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

TCOV

Trust Company of Vermont Brattleboro, Vermont $2.68B AUM

CFGS

Concourse Financial Group Securities Birmingham, Alabama $1.77B AUM 17.37% 1-Year Est. Return

Crescent Grove Advisors's SRNE Position: Q2 2023 in Review

Crescent Grove Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2023, closing a stake of 60,000 shares — an estimated $21.6K sold.

Crescent Grove Advisors first reported a position in SRNE in Q2 2021 and held it in 8 quarters. The position peaked at $200K in Q4 2021. 9 funds tracked by Wall St. Rank hold SRNE as of Q2 2023.

Crescent Grove Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
Crescent Grove Advisors sold 60,000 Sorrento Therapeutics, Inc. shares in Q2 2023, an estimated $21.6K.
Crescent Grove Advisors first reported a position in Sorrento Therapeutics, Inc. in Q2 2021 and held it in 8 quarters.
Crescent Grove Advisors's Sorrento Therapeutics, Inc. position peaked at $200K in Q4 2021.
9 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2023.

Based on Crescent Grove Advisors's 13F filing for Q2 2023, filed 13 Jul 2023.